PRKDC and prostate carcinoma: For example, Goodwin et al. demonstrated that in prostate cancer, DNA-PK interacted with the androgen receptor (AR) at DNA transcriptional sites where it facilitated AR-dependent transcriptional transactivation (46) of a panel of genes that drive prostate cancer progression.